Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: The advent of precision medicine and clinical implementation of genomic technologies continues to provide physicians and patients with critical information that can affect therapeutic choices. The primary challenge for frontline physicians is interpreting genomic test results and prioritizing treatment options identified by genomic test results. The published literature and clinical trial information remains insufficient to provide unequivocal answers as to therapeutic choices. The solution at many institutions has been to implement a molecular tumor board comprised of experts in genomics who share basic and clinical scientific knowledge, n of 1 (or of few) experiences, to provide consensus interpretations of targeted treatment options offered by genomic test results. While many versions of a molecular tumor board exist across the United States, both Intermountain Healthcare and Stanford University have each conducted regular molecular tumor board reviews of active patient cases since 2013. In addition to interpreting genomic test results and providing guidance on treatment options, these Molecular Tumor Boards have the opportunity to learn from each patient encounter, track and collate outcomes, and disseminate the information, where possible, so that other patients can benefit.
At the PMWC2018, this session will demonstrate the operation of a Molecular Tumor Board – with a patient in need of a decision regarding therapy – and discuss the necessary components for establishing and operating such entities.
Session Chair Profile
M.D., Ph.D., Executive Director of Precision Medicine & Precision Genomics, Intermountain Healthcare
Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare. Dr. Nadauld recently participated in the Precision Medicine Initiative Summit and roundtables at the White House with President Barack Obama. He also attended Vice President Joe Biden’s Cancer Moonshot Summit, where the Oncology Precision Network (OPeN), spearheaded by Dr. Nadauld, was mentioned among the Vice President’s remarks. OPeN is a consortium of healthcare partners working to advance data-sharing in precision medicine, including genomic information and outcomes. Dr. Nadauld completed his undergraduate education at Brigham Young University, and went on to complete combined MD/PhD and clinical training at the University of Utah. He completed clinical training in Medical Oncology at Stanford University School of Medicine, where he completed a postdoctoral fellowship in solid tumor genomics.
M.D., Associate Professor of Medicine and Genetics, Stanford University School of Medicine
Dr. Ford’s overall research goals are to understand the role of genetic changes in cancer genes in the risk and development of solid tumors. The laboratory focuses on how DNA repair and DNA damage response pathways are critical to tumorigenesis and are potential candidates for targeted therapeutics and prevention. Dr. Ford also directs the Stanford Cancer Genetics Clinic. Dr. Ford has extensive experience in training and mentoring students, fellows and junior faculty members in biomedical sciences and translational research, and many former students and fellows have gone onto faculty positions at prestigious academic centers. He is the Director of the Stanford Oncology Fellowship Training Program and PI of an NCI-supported T32 training grant. In summary, Dr. Ford has a demonstrated record of successful laboratory and translational clinical research, and a track record of mentoring physician-investigators into independent academic careers.